Cargando…

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

BACKGROUND: Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6–17 years) with moderate‐to‐severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk–benefit profile in younger children remains a significant unmet need. OBJECTIVES: To det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paller, A.S., Siegfried, E.C., Simpson, E.L., Cork, M.J., Lockshin, B., Kosloski, M.P., Kamal, M.A., Davis, J.D., Sun, X., Pirozzi, G., Graham, N.M.H., Gadkari, A., Eckert, L., Ruddy, M., Bansal, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Allergy and Eczema
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894166/ https://www.ncbi.nlm.nih.gov/pubmed/32893393 http://dx.doi.org/10.1111/jdv.16928

Ejemplares similares

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
por: Roekevisch, E., et al.
Publicado: (2020)

Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema
por: Howells, L., et al.
Publicado: (2019)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Validation of the Patient‐Oriented SCORing for Atopic Dermatitis tool for black skin
por: Faye, O., et al.
Publicado: (2019)

Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitized
por: Boonstra, M., et al.
Publicado: (2018)

The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
por: van der Kraaij, G.E., et al.
Publicado: (2020)

Stepwise approach of development of dermo‐cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance
por: Ribet, V., et al.
Publicado: (2019)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
por: Pereira, M.P., et al.
Publicado: (2018)

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
por: Cork, M.J., et al.
Publicado: (2020)

Relations between a standardized experimental stressor and cutaneous sensory function in patients with chronic pruritus and healthy controls: an experimental case–control study
por: Schneider, G., et al.
Publicado: (2018)

Emollient efficacy and acceptability in the treatment of eczematous dry skin: A double-blind, randomised comparison of two UK-marketed products
por: Djokic-Gallagher, Jasmina, et al.
Publicado: (2016)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2019)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
por: Paller, Amy S., et al.
Publicado: (2023)

Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
por: Beck, L.A., et al.
Publicado: (2020)

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
por: Cork, Michael J., et al.
Publicado: (2023)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Determinants of uncontrolled allergic rhinitis in Kinshasa hospitals
por: Kakobo, Patricia K., et al.
Publicado: (2023)

Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
por: López-Viña, Antolín, et al.
Publicado: (2022)

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2021)

Corrigendum: Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
por: López-Viña, Antolín, et al.
Publicado: (2023)

Early inhalant allergen sensitization at component level: an analysis in atopic Dutch children
por: Landzaat, Lonneke J., et al.
Publicado: (2023)

Proteomics Profiling to Distinguish DOCK8 Deficiency From Atopic Dermatitis
por: Jacob, Minnie, et al.
Publicado: (2021)

Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients
por: Viskens, An-Sofie, et al.
Publicado: (2022)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
por: Ayasse, Marissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j6hi8e10raekf7960b5cpbnc1r